The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics

EJS Sonuga-Barke - Neuroscience & biobehavioral reviews, 2003 - Elsevier
The currently dominant neuro-cognitive model of Attention Deficit Hyperactivity Disorder
(AD/HD) presents the condition as executive dysfunction (EDF) underpinned by …

The top and the bottom of ADHD: a neuropsychological perspective

JA Sergeant, H Geurts, S Huijbregts, A Scheres… - Neuroscience & …, 2003 - Elsevier
Five models of attention deficit/hyperactivity disorder (ADHD) are reviewed. It is proposed
that the cognitive-energetic model provides a reasonably comprehensive account of ADHD …

[HTML][HTML] The worldwide prevalence of ADHD: is it an American condition?

SV Faraone, J Sergeant, C Gillberg… - World psychiatry, 2003 - ncbi.nlm.nih.gov
Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder that affects up to 1 in
20 children in the USA. The predominance of American research into this disorder over the …

Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD

ND Volkow, JM Swanson - American Journal of Psychiatry, 2003 - Am Psychiatric Assoc
OBJECTIVE: Methylphenidate, the most common treatment for attention deficit hyperactivity
disorder (ADHD), increases extracellular dopamine in the brain, which is associated with its …

A review of the biological bases of ADHD: what have we learned from imaging studies?

S Durston - Mental retardation and developmental disabilities …, 2003 - Wiley Online Library
Abstract Attention Deficit Hyperactivity Disorder (ADHD) is a common and impairing
neuropsychiatric disorder with onset at preschool age. Although a significant amount of …

Methylphenidate treatment during pre-and periadolescence alters behavioral responses to emotional stimuli at adulthood

CA Bolanos, M Barrot, O Berton, D Wallace-Black… - Biological …, 2003 - Elsevier
BACKGROUND: Methylphenidate (MPH) is a psychomotor stimulant medication widely used
for the treatment of attention-deficit/hyperactivity disorder (ADHD). Given the extent of …

Enduring behavioral effects of early exposure to methylphenidate in rats

WA Carlezon Jr, SD Mague, SL Andersen - Biological psychiatry, 2003 - Elsevier
BACKGROUND: Methylphenidate (MPH) is a stimulant prescribed for the treatment of
attention-deficit/hyperactivity disorder (ADHD). Stimulant drugs can cause enduring …

Advances in the pharmacotherapy of attention‐deficit‐hyperactivity disorder: Focus on methylphenidate formulations

JS Markowitz, AB Straughn… - … : The Journal of Human …, 2003 - Wiley Online Library
The psychostimulant dl‐methylphenidate (MPH) remains the most common drug therapy in
child and adolescent psychiatry for the treatment of attention‐deficit‐hyperactivity disorder …

A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11

MN Ogdie, IL Macphie, SL Minassian, M Yang… - The American Journal of …, 2003 - cell.com
Attention-deficit/hyperactivity disorder (ADHD [MIM 143465]) is a common, highly heritable
neurobehavioral disorder of childhood onset, characterized by hyperactivity, impulsivity …

Dopamine genes and attention-deficit hyperactivity disorder: a review

S DiMaio, N Grizenko, R Joober - Journal of Psychiatry and Neuroscience, 2003 - jpn.ca
Objective: To review the results of genetic studies investigating dopamine-related genes in
attention-deficit hyperactivity disorder (ADHD). Data sources: Papers (association/linkage …